Development of Highly Multiplexed Raman Imaging Platform for Alzheimer’s Disease
Project Number1K99EB035706-01A1
Former Number1K99EB035706-01
Contact PI/Project LeaderEREMINA, OLGA E.
Awardee OrganizationUNIVERSITY OF SOUTHERN CALIFORNIA
Description
Abstract Text
PROJECT SUMMARY
The immune system plays a significant role in aging and in autoimmune, neurodevelopmental, and
neurodegenerative diseases. Functionally diverse immune cells change with disease progression and shape
disease pathology through complex mechanisms. Current molecular imaging techniques do not allow for
simultaneous interrogation of multiple biomarkers from a single tissue sample. In the proposed preclinical study,
I will develop a nanoparticle-based Raman imaging approach capable of highly multiplexed molecular spatial
profiling of brain histology sections of Alzheimer’s disease (AD) patients. There is a critical need to improve our
understanding of brain immunity to offer intervention tools for designing new therapeutic strategies for treating
and preventing brain pathologies. My new multiplexed imaging platform will identify and capture the underlying
cellular and phenotypic diversity in intricate neural tissues within the spatial context of the brain. Sharp and
unique spectral barcodes of the carefully selected ensemble of surface-enhanced Raman scattering (SERS)
nanoparticles (NPs) will ensure reliable and accurate spectral unmixing. During the K99 mentored phase, I will
design NP constructs exhibiting strong and unique Raman scattering signals (SA1). Unlike traditional imaging
techniques, the developed SERS NPs will be capable of visualizing at least 30 biomarkers in a single imaging
acquisition. I will validate the high spectral specificity and quantitative accuracy of the spectral unmixing. In SA2,
the NPs will be decorated with biotargeting species to ensure highly specific recognition of immune-brain
biomarkers in cell culture and tissue sections. An innovative strategy will be used to stain and image archived
patient samples starting with single plex Raman imaging and correlated with the gold standard IHC histology. As
an independent investigator, I will use targeted SERS NPs to produce highly multiplexed proteomic images of
brain tissue. To confirm the sensitivity and specificity of the Raman imaging approach, the adjacent tissue
sections will be assessed by IHC and conventional immunofluorescence imaging. These highly multiplexed
molecular maps of the brain-immune spatial biology will pave the way for future studies focused on improving
our ability to understand, prevent, and treat AD. I have a unique set of expertise in SERS imaging and believe I
am highly qualified to lead and conduct the proposed project at the University of Southern California. I also have
identified the following key areas which require additional training to support my transition to independence: (1)
quantitative spectral unmixing and image processing; (2) active cell targeting; (3) histopathological evaluation of
postmortem brain tissue with a solid knowledge base in AD biology. I have deliberately chosen and carefully
assembled a world-class committee of mentors and advisors including my primary mentor Dr. Cristina Zavaleta
and co-mentor Dr. Peter Y. Wang. My mentors are in full support of my research and career goals. I am
committed to the research proposed here and strongly believe that it will help me gain the necessary training
required to enable my long-term career goal of being an established investigator in the field of molecular imaging.
Public Health Relevance Statement
PROJECT NARRATIVE
Immune cells have recently been recognized as vital players in Alzheimer’s disease, as they change with disease
progression and can shape the disease pathology through complex mechanisms. We require a new imaging tool
to closely study various immune cell populations simultaneously within the spatial context of human brain tissue.
The complete molecular mapping of the brain-immune relationship, enabled by our Raman imaging approach,
will pave the way for improving our ability to understand, prevent, and treat Alzheimer’s disease.
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
072933393
UEI
G88KLJR3KYT5
Project Start Date
01-January-2025
Project End Date
31-December-2026
Budget Start Date
01-January-2025
Budget End Date
31-December-2025
Project Funding Information for 2025
Total Funding
$124,562
Direct Costs
$115,335
Indirect Costs
$9,227
Year
Funding IC
FY Total Cost by IC
2025
National Institute of Biomedical Imaging and Bioengineering
$124,562
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1K99EB035706-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1K99EB035706-01A1
Patents
No Patents information available for 1K99EB035706-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1K99EB035706-01A1
Clinical Studies
No Clinical Studies information available for 1K99EB035706-01A1
News and More
Related News Releases
No news release information available for 1K99EB035706-01A1
History
No Historical information available for 1K99EB035706-01A1
Similar Projects
No Similar Projects information available for 1K99EB035706-01A1